Cancer chemotherapy-induced peripheral neuropathy (CIN) is the most common and serious neurologic complication of cancer treatment. CIN can occur with the most commonly used chemotherapy (CTX) drugs including platinum compounds; taxanes; plant alkaloids; antiangiogenesis agents; and proteasome inhibitors. CIN can result in treatment delays or cessation of treatment which may lead to disease progression and decreased survival. The specific aims of this study in oncology patients with and without CIN who have completed CTX are to: evaluate for differences in sensory and motor characteristics of patients with and without CIN, evaluate for differences in mood, concurrent symptoms, balance, and quality of life in patients with and without CIN, and evaluate for genetic differences, in patients with and without CIN.
The purpose of this study at the University of California, San Francisco is to better understand the signs and symptoms of chemotherapy neuropathy and the genetic (inherited) factors that increase risk of developing it.
The researchers wanted to enroll up to 600 volunteers near San Francisco and they enlisted the Army of Women (AOW) to support the final stages of their recruitment efforts. The Call to Action for this study was sent to AOW members on June 10, 2015, and the researchers closed enrollment on Nov. 23, 2015, after the AOW provided them with 106 women who were interested in enrolling in the study.